CSTL News and Press, Castle Biosciences Inc. From 09/17/25

FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The rankin...

FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification provided by its TissueCypher Barrett&#...

2025-09-02 09:14:49 ET Investment Thesis The first question I consider when I think of a company in molecular diagnostics is whether it can translate complex science into a commercially viable business. A lot of companies develop tests that are really exciting, but they are unab...

2025-08-28 09:52:41 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fi...

New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making thresholds for adjuvant radiation thera...

2025-08-04 22:22:36 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript Castle Biosciences Q2 2025 Earnings Preview Castle Biosciences, Revolution Medicines get FDA breakthrough statuses Seeking Alpha’s Quant ...

2025-08-04 22:21:49 ET Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek J. Maetzold - Founder, CEO, President & ...

2025-08-04 16:16:47 ET More on Castle Biosciences Castle Biosciences Q2 2025 Earnings Preview Castle Biosciences, Revolution Medicines get FDA breakthrough statuses Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle ...

Delivered Q2 2025 revenue of $86 million Q 2 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 33% over Q 2 2024 Raising full-year 2025 revenue guidance range to $310-3...

2025-08-04 10:00:00 ET Major earnings expected after the bell on Monday include: Palantir Technologies ( PLTR ) Simon Property Group ( SPG ) MercadoLibre ( MELI ) ONEOK ( OKE ) Vertex Pharmaceuticals Incorporated ( VRTX ) Read the full artic...